mRNA

News

Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.

Event

Partner Content

Advancing mRNA's Therapeutic Potential to Combat All Diseases

News

Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.

R&D

The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.

News

The UK government has celebrated the opening of Moderna's £150m vaccines facility, but storm clouds continue to gather on the issue of drug pricing.

News

BioNTech's takeover of CureVac seems to have unlocked a resolution to some of the patent litigation swirling around mRNA vaccine technologies.